Supriya LifescienceNSE:SUPRIYA -1.62%75 ROE % is 24.79% as of Mar. 2026, which is 10% below its 10-year median of 27.54. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 75/100 and a GF Value™ of ₹805.46 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,250 Biotechnology companies, Supriya Lifescience ranks better than 92.4% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Supriya Lifescience ROE % Related Terms
Supriya Lifescience ROE % Historical Data
* Premium members only.
The historical data trend for Supriya Lifescience's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Supriya Lifescience's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supriya Lifescience ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Supriya Lifescience's ROE % distribution charts can be found below:
* The bar in red indicates where Supriya Lifescience's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Supriya Lifescience (NSE:SUPRIYA) has a ROE % of 24.79% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Supriya Lifescience and its competitors. This is 10% below median its historical median of 27.54. Over the past decade, Supriya Lifescience's ROE % has ranged from 13.66 to 60.42. According to the industry distribution chart, Supriya Lifescience ranks #95 out of 1250 companies in the Biotechnology industry, placing it in the top 7.6%.
Is Supriya Lifescience's ROE % too high?
Supriya Lifescience's current ROE % of 24.79% is 10% below median its 10-year median of 27.54. Over the past 10 years, this metric has ranged from a low of 13.66 to a high of 60.42. Based on the distribution chart, Supriya Lifescience ranks #95 out of 1250 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Supriya Lifescience has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Supriya Lifescience ranks #95 out of 1250 companies for ROE %. This places Supriya Lifescience in the top 8% of its industry — outperforming the majority of peers. Historically, Supriya Lifescience's own ROE % has ranged from 13.66 to 60.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Supriya Lifescience and its competitors. Supriya Lifescience's current ROE % is 24.79%, which is 10% below median its own 10-year median of 27.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹805.46, compared to a current price of ₹978.90 — trading 21.5% above its estimated fair value. The current ROE % is 24.79%, which is 10% below median its 10-year median of 27.54. Supriya Lifescience's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current ROE % is 24.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?
Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued.
The current stock price of ₹978.90 is trading 21.5% above its estimated GF Value™ of ₹805.46.
GuruFocus considers Supriya Lifescience to be Modestly Overvalued.
Key valuation signals for NSE:SUPRIYA:
ROE %: 24.79% (10% below median its 10-year median of 27.54)
GF Value™: ₹805.46 vs. price of ₹978.90 (21.5% above fair value)
No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
75GF Score
Get the complete analysis for NSE:SUPRIYA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUPRIYA has been successfully added to your 
